Patrick Morgante, DO
Family Medicine · Havelock, NCNPI 1881655371
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,783 of the $2,434 with a category attached, or 73.3%. Modernatx, Inc. accounts for 61.2% of it on its own, with 3 other manufacturers making up the rest.
Across 16 payments — averaging $152.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Modernatx, Inc.$1K
- Amgen$833
- Organon$69
- Boston Scientific$42
Across 107 payments — averaging $47,027 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Vertex$2.2M
- Modernatx, Inc.$1.3M
- Eli Lilly$915K
- Amgen$543K
- E.r. Squibb & Sons, L.L.C.$65K
- Cleerly, Inc.$25K
What the payments were for
- Travel & lodging$1,78373%
- Food & beverage$65127%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Modernatx, Inc. | 8 | $1,490 |
| Amgen | 5 | $833 |
| Organon | 2 | $69 |
| Boston Scientific | 1 | $42 |
How this compares
$2,434 in reported general payments places this provider in the 80th percentile of 3,444 family medicine providers in North Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 52 | $62,279 |
| OzempicSemaglutide | 33 | $47,475 |
| EliquisApixaban | 35 | $43,361 |
| JardianceEmpagliflozin | 18 | $19,383 |
| JanuviaSitagliptin Phosphate | 13 | $16,596 |
| XareltoRivaroxaban | 12 | $14,164 |
| TrulicityDulaglutide | 12 | $12,967 |
| LinzessLinaclotide | 20 | $11,609 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 17 | $6,478 |
| Rosuvastatin Calcium | 266 | $3,660 |
| Atorvastatin Calcium | 185 | $2,156 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 11 | $1,898 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 11 | $1,837 |
| Levothyroxine Sodium | 123 | $1,725 |
| Telmisartan | 30 | $1,363 |
Paid to pharmacies, not to this prescriber.
Other family medicine in Havelock
- William CromwellRaleigh$879K
- Steve VacalisGastonia$693K
- David DundeeWinston Salem$633K
- Kevin SodenCharlotte$558K
- Brian ForrestApex$398K
- Joseph KonenCharlotte$322K
- Richard RachimaCharlotte$294K
- Dimitrios HondrosCharlotte$275K
- Domingo Rodriguez-CueGarner$253K
- Christopher ChaoCary$201K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.